Market revenue in 2023 | USD 1,182.5 million |
Market revenue in 2030 | USD 2,400.9 million |
Growth rate | 10.6% (CAGR from 2023 to 2030) |
Largest segment | Nucleic acid amplification test |
Fastest growing segment | Next Generation Sequencing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Nucleic Acid Amplification Test, ELISA, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting |
Key market players worldwide | Abbott Laboratories, Danaher Corp, Becton Dickinson & Co, Bio-Rad Laboratories Inc, Roche Holding AG, Grifols SA Ordinary Shares - Class A, Siemens AG, Thermo Fisher Scientific Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood screening market will help companies and investors design strategic landscapes.
Nucleic acid amplification test was the largest segment with a revenue share of 40.11% in 2023. Horizon Databook has segmented the North America blood screening market based on nucleic acid amplification test, elisa, chemiluminescence immunoassay, next generation sequencing, western blotting covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America blood screening market, including forecasts for subscribers. This continent databook contains high-level insights into North America blood screening market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account